Anika Therapeutics, Inc.ANIK

NasdaqHealthcareSurgical & Medical Instruments & Apparatus
Price (close)
$20.37
Market cap
$272.6M
P/E
—
Revenue (TTM)
$120.7M
Net income
-$3.8M
Dividend yield
—
1-year total return
126.3%
Net margin
-3.1%
Revenue growth
5.3%
Debt / equity
—

What Anika Therapeutics, Inc. does.

Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide.

In October 2024, we announced a strategic shift to concentrate on our OA Pain Management and Regenerative Solutions portfolios. This strategic decision involved the sale of Arthrosurface Incorporated on October 31, 2024 and the sale of Parcus Medical, LLC on March 7, 2025, both of which were acquired in early 2020 under a previous management strategy.

As we look ahead, our focused strategy, driven by HA-based products, positions us to offer truly innovative treatments in areas of unmet need and substantial, growing markets. We will place particular emphasis on the commercial execution and adoption of the newest product in our Regenerative Solutions portfolio, the Integrity Implant System (“Integrity”), a HA-based scaffold designed for rotator cuff and other tendon repairs. The Integrity system has shown strong performance, with continuing growth in surgeries and significant adoption by new customers.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$130.5M$147.8M$113.8M$120.8M$119.9M$112.8M
Net income-$24.0M$4.1M-$14.9M-$82.7M-$56.4M-$10.9M
Free cash flow$11.4M$3.3M-$3.1M-$7.2M-$2.3M$4.4M

More on ANIK.

Figures from Anika Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.